<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1.  </label>
 <caption>
  <p>dsRNA based drugs: modern trends of pharmaceutical developments</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left">Name</th>
    <th valign="top" align="left">Structure</th>
    <th valign="top" align="left">Developer</th>
    <th valign="top" align="left">Current status</th>
    <th valign="top" align="left">Prescription</th>
    <th valign="top" align="left">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6">Natural dsRNAs</td>
   </tr>
   <tr>
    <td valign="top" align="left">Ridostin</td>
    <td valign="top" align="left">Mixture of dsRNA and single stranded RNA from 
     <italic>Saccharomyces cerevisiae</italic>
    </td>
    <td valign="top" align="left">SRC VB “Vector” (Russia)</td>
    <td valign="top" align="left">Approved for medical application</td>
    <td valign="top" align="left">Influenza, herpes, chlamydia, tick-borne encephalitis</td>
    <td valign="top" align="left">53, 91, 101</td>
   </tr>
   <tr>
    <td valign="top" align="left">Ridostin Pro</td>
    <td valign="top" align="left">Mixture of dsRNA and single stranded RNA from 
     <italic>Saccharomyces cerevisiae</italic>, stabilized with polyvinylpyrrolidone
    </td>
    <td valign="top" align="left">SRC VB “Vector” (Russia)</td>
    <td valign="top" align="left">Registration stage</td>
    <td valign="top" align="left">Influenza, SARS</td>
    <td valign="top" align="left">81</td>
   </tr>
   <tr>
    <td valign="top" align="left">Larifan</td>
    <td valign="top" align="left">DsRNA of phage f2 </td>
    <td valign="top" align="left">Larifan Ltd. (Latvia)</td>
    <td valign="top" align="left">Approved for medical application</td>
    <td valign="top" align="left">Arbovirus and rhabdovirus infections, herpetic diseases</td>
    <td valign="top" align="left">54, 56</td>
   </tr>
   <tr>
    <td valign="top" align="left">Rifastin</td>
    <td valign="top" align="left">DsRNA of phage φ6 </td>
    <td valign="top" align="left">SRC VB “Vector” (Russia)</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">Viral infections (Omsk hemorrhagic fever, influenza)</td>
    <td valign="top" align="left">55–57</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="6">Double-stranded complexes of complementary homopolynucleotides</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="6">PolyA:PolyU</td>
   </tr>
   <tr>
    <td valign="top" align="left">Poludan</td>
    <td valign="top" align="left">Double-stranded complex polyriboadenylic and polyribouridylic acids</td>
    <td valign="top" align="left">LANS-Pharm Ltd. (Russia)</td>
    <td valign="top" align="left">Approved for medical application</td>
    <td valign="top" align="left">Viral eye diseases (adenovirus and herpetic infections), influenza and SARS</td>
    <td valign="top" align="left">61, 62, 122, 123</td>
   </tr>
   <tr>
    <td valign="top" align="left">Polyadenur</td>
    <td valign="top" align="left">Double-stranded complex polyriboadenylic and polyribouridylic acids</td>
    <td valign="top" align="left">Beaufour Ipsen (France), Hemispherx Biopharma (USA)</td>
    <td valign="top" align="left">Clinical trials</td>
    <td valign="top" align="left">Hepatitis B and C (as a part of IFN-α based complex therapy), breast cancer</td>
    <td valign="top" align="left">63–65</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="6">PolyG:PolyC</td>
   </tr>
   <tr>
    <td valign="top" align="left">Polyguacyl</td>
    <td valign="top" align="left">Double-stranded complex of polyriboguanylic and polyribocytidylic acids</td>
    <td valign="top" align="left">SRC VB “Vector” (Russia)</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">Viral infections (caused by viruses of encephalomyocarditis, tick-borne encephalitis, vesicular stomatitis)</td>
    <td valign="top" align="left">46, 61, 66, 67</td>
   </tr>
   <tr>
    <td valign="top" align="left">RGC100</td>
    <td valign="top" align="left">Double-stranded complex of polyriboguanylic and polyribocytidylic acids (100 bp)</td>
    <td valign="top" align="left">Riboxx GmbH (Germany)</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">To increase efficiency of vaccination (activation of dendritic cells, T-cell proliferation)</td>
    <td valign="top" align="left">46</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="6">PolyI:PolyC</td>
   </tr>
   <tr>
    <td valign="top" align="left">PolyI:PolyC</td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic and polyribocytidylic acids</td>
    <td valign="top" align="left">University of Alabama at Birmingham, Hemispherx Biopharma, Inc. (USA); Medical University of South Carolina, Gibbs Cancer Center and Research Institute, Eli Lilly and Company (USA), etc.</td>
    <td valign="top" align="left">Clinical trials</td>
    <td valign="top" align="left">Hepatocellular carcinoma, hepatitis B, influenza</td>
    <td valign="top" align="left">71–74, 76</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td valign="top" align="left">Institute of Pharmaceutical Sciences, Institute of Molecular Biology and Biophysics (Switzerland); Nanjing Agricultural University (China); Icahn School of Medicine at Mount Sinai (USA); Yonsei University (South Korea); The University of Tokyo (Japan), etc.</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">For antitumor therapy of malignant neoplasms of different localization, enhancement of immunogenicity of antitumor vaccines</td>
    <td valign="top" align="left"> 88, 99, 100, 104, 105, 106, 109–112, 115, 117–121</td>
   </tr>
   <tr>
    <td valign="top" align="left">uPIC100-400</td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic and polyribocytidylic acids (100–400 bp)</td>
    <td valign="top" align="left">
     <p>Kyowa Hakko Bio Co., Ltd., Hofu (Japan);</p>
     <p>Hokkaido University, Sapporo (Japan)</p>
    </td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">For prophylaxis and treatment of infectious and oncological diseases</td>
    <td valign="top" align="left">78</td>
   </tr>
   <tr>
    <td valign="top" align="left">
     <p>PolyI:PolyC,</p>
     <p>modified</p>
    </td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic and polyribocytidylic acids modified by polymers and/or encapsulated into particles</td>
    <td valign="top" align="left">Research laboratories in Germany, China, Italy, the Netherlands, Canada, Belgium, Australia, USA</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">Oncological diseases of various localization (glioblastoma, adenocarcinoma, breast cancer, melanoma)</td>
    <td valign="top" align="left">74, 79–81, 92–96, 108, 116</td>
   </tr>
   <tr>
    <td valign="top" align="left">
     <p>Hitonol, </p>
     <p>PolyICLC</p>
    </td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic and polyribocytidylic acids with non-covalent adduct of poly-L-lysine and carboxymethylcellulose</td>
    <td valign="top" align="left">Oncovir, Inc., Washington, DC (USA)</td>
    <td valign="top" align="left">Clinical and laboratory trials</td>
    <td valign="top" align="left">Oncological diseases of various localization, including inoperable cancer cases, viral infections, increased immunogenicity of vaccines</td>
    <td valign="top" align="left">74, 76, 82–87, 97, 98</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="6">Double-stranded complexes of homopolyribonucleotide and polyribonucleotide copolymer</td>
   </tr>
   <tr>
    <td valign="top" align="left">
     <p>Ampligen</p>
     <p>Atvogen</p>
     <p>Rintatolimod</p>
     <p>Rintamod®</p>
     <p>PolyI:PolyC
      <sub>12</sub>U
     </p>
    </td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic acid and copolymer of polyribocytidylic and uridylic acids (at a ratio 12 : 1)</td>
    <td valign="top" align="left">Hemispherx Biopharma, Inc., Philadelphia, PA (USA)</td>
    <td valign="top" align="left">Clinical trials. Approved for medical application (Argentina) </td>
    <td valign="top" align="left">
     <p>Complex therapy of syndromes of chronic fatigue and acquired immunodeficiency syndrome (AIDS), breast cancer, liver, prostate, ovarian cancer, colorectal cancer, mesothelioma</p>
     <p>Severe cases of myalgic encephalomyelitis/chronic fatigue syndrome</p>
    </td>
    <td valign="top" align="left">75, 76</td>
   </tr>
   <tr>
    <td valign="top" align="left">PolyI:PolyC
     <sub>30</sub>U
    </td>
    <td valign="top" align="left">Double-stranded complex of polyriboinosinic acid and copolymer of polyribocytidylic and uridylic acids (at a ratio 30 : 1)</td>
    <td valign="top" align="left">Hemispherx Biopharma, Inc., Philadelphia, PA (USA)</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">For the prevention and treatment of infectious and oncological diseases</td>
    <td valign="top" align="left">75, 77</td>
   </tr>
   <tr>
    <td valign="top" align="left">RGIC100 PolyGI:PolyC</td>
    <td valign="top" align="left">Double-stranded complex of polyribocytidylic acid and copolymer of polyguanylic and polyriboinosinic acids (100 bp)</td>
    <td valign="top" align="left">Riboxx GmbH (Germany)</td>
    <td valign="top" align="left">Laboratory studies</td>
    <td valign="top" align="left">For the prevention and treatment of infectious and oncological diseases</td>
    <td valign="top" align="left">68</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
